

| Patient Information | | | | | | | | | |
|---|---|--|--|--|--|--|--|--|--|
| Last Name: | | | | | | | | | |
| First Name: | MI: Sex:□M □F | | | | | | | | |
| DOB(mm/dd/yyyy): | SSN: | | | | | | | | |
| Parent/Guardian (if applicable): | | | | | | | | | |
| (REQUIRED if patient is <18 years old at time of sample collection) | | | | | | | | | |
| Address: | City: | | | | | | | | |
| State:Zip:Phone: | | | | | | | | | |
| | ICD-10 Diagnosis Code(s) | | | | | | | | |
| Primary ICD-10 Code (REQUIRED) | Additional ICD-10 Code(s) (OPTIONAL) | | | | | | | | |
| 1 | 2 3 4 | | | | | | | | |
| | Billing Information | | | | | | | | |
| BILL: | | | | | | | | | |
| Insurance Carrier: | Policy #: | | | | | | | | |
| | ovider/Account Information | | | | | | | | |
| Account Name/Address | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | _ | | | | | | | | |
| Phone: | Fax: | | | | | | | | |
| | rider Selection & Signature (REQUIRED) | | | | | | | | |
| | Clearly select the ordering provider from list below (circle or √). If provider is not listed, please provide their FULL NAME AND NPI: | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | NPI: | | | | | | | | |
| care, and/or treatment of t | is/are reasonable and medically necessary for the diagnosis, his patient's condition as documented in the medical record. | | | | | | | | |
| | s old at the time of testing, the parent/guardian has been eresponsible for any costs associated with testing. | | | | | | | | |
| | netic testing: I have read and understand the genetic consent and acknowledge I have obtained consent from my patient. | | | | | | | | |
| roqui omone on page eno | ana asianomoago ano oscanica conicent no , patiena | | | | | | | | |
| Signature: | | | | | | | | | |
| Name: | D-t | | | | | | | | |
| | Date: | | | | | | | | |
| Sa | mple Collection Information | | | | | | | | |
| Sa Date (mm/dd/yyyy): | mple Collection Information | | | | | | | | |
| Date (mm/dd/yyyy): | mple Collection Information | | | | | | | | |
| Date (mm/dd/yyyy): Patient ID: | mple Collection Information | | | | | | | | |
| Date (mm/dd/yyyy): Patient ID: | Time:AM PM | | | | | | | | |
| Date (mm/dd/yyyy): Patient ID: MEDICARE ONLY - HO | Time:AM PM Sender Sample ID: SPITAL STATUS WHEN SAMPLE WAS COLLECTED:Non-Hospital Patient | | | | | | | | |
| Date (mm/dd/yyyy): Patient ID: MEDICARE ONLY - HO Hospital Inpatient | Time:AM PM Sender Sample ID: SPITAL STATUS WHEN SAMPLE WAS COLLECTED:Non-Hospital Patient | | | | | | | | |
| Date (mm/dd/yyyy): Patient ID: MEDICARE ONLY - HO Hospital Inpatient | Time:AM PM Sender Sample ID: SPITAL STATUS WHEN SAMPLE WAS COLLECTED:Non-Hospital Patient | | | | | | | | |
| Date (mm/dd/yyyy): Patient ID: MEDICARE ONLY - HO Hospital Inpatient Laboratory/Other Name | Time:AM PM Sender Sample ID: DSPITAL STATUS WHEN SAMPLE WAS COLLECTED: Non-Hospital Patient ### Non-Hospital Patient ### Address: | | | | | | | | |
| Date (mm/dd/yyyy): Patient ID: MEDICARE ONLY - HO | Time:AM PM Sender Sample ID: SPITAL STATUS WHEN SAMPLE WAS COLLECTED:Non-Hospital Patient | | | | | | | | |

IBD: Inflammatory bowel disease; UC: Ulcerative colitis; CD: Crohn's disease; TPMT: thiopurine methyltransferase; HCV: Hepatitis C; NASH: Non-alcoholic steatohepatitis

All information requested is REQUIRED to process testing and/or submit insurance claims on your patient's behalf.

Prometheus Client Services | 888-423-5227 | 6:00 am - 4:30 pm Pacific Time

| Simultaneously measures serum risankizumab (RZB) & antibodies-to-RZB (ATR Anser Testing - Biologic Dosing Data (optional) Date of Last Dose Current Current (mm/dd/yyyy) Dose Interval □mg □days | | Sele | ct Test(s) To | Be Perfor | med | |
|--|---|--|---|---|------------------------------------|--------------------|
| Simultaneously measures serum infliximab (IFX) & antibodies-to-IFX (ATI). Select bloogic (optional): REMICADE* (infliximab) INFLECTRA* (IFX-dyyb) RENFLEXIS* (IFX-abd AVSOLA* (IFX-axxq) Other IFX: Anser* ADA (#3170) Simultaneously measures serum adalimumab (ADA) & antibodies-to-ADA (ATA Select biologic (optional): HUMIRA* (odalimumab) Other ADA: Anser* VDZ (#3180) Simultaneously measures serum vedolizumab (VDZ) & antibodies-to-VDZ (ATV Select biologic (optional): Simultaneously measures serum ustekinumab (UST) & antibodies-to-UST (ATV Select biologic (optional): STELARA* (ustekinumab) Other UST: Anser* RZB (#3140) Simultaneously measures serum risankizumab (RZB) & antibodies-to-RZB (ATR Anser* Testing - Biologic Dosing Data (optional) Date of Last Dose Current Cur | | — Th | erapeutic Dr | ug Monito | ring — | |
| Anser® ADA (#3170) Simultaneously measures serum adalimumab (ADA) & antibodies-to-ADA (ATA Select biologic (optional): □ HMURKA' (dadlimumab) | Simulta Select | neously measur biologic (optio CADE® (infliximal | res serum inflixir nal): D) | 'RA ® (IFX-dyyb) | | |
| Simultaneously measures serum adalimumab (ADA) & antibodies-to-ADA (ATA Select biologic (optional): HMMIRA' (adalimumab) Other ADA: | | | _ | | | |
| Simultaneously measures serum vedolizumab (VDZ) & antibodies-to-VDZ (ATV Anser® UST (#3190) Simultaneously measures serum ustekinumab (UST) & antibodies-to-UST (ATU | Simulta Select | neously measur biologic (optio | es serum adalin nal): | , , | & antibodies-to | -ADA (ATA) |
| Simultaneously measures serum ustekinumab (UST) & antibodies-to-UST (ATU Select biologic (optional): STELARA' (ustekinumab) Other UST: | | , | | zumab (VDZ) | & antibodies-to | o-VDZ (ATV) |
| Simultaneously measures serum risankizumab (RZB) & antibodies-to-RZB (ATE Anser Testing - Biologic Dosing Data (optional) Date of Last Dose Current Current Interval Gurent | Simulta Select | neously measur biologic (optio | es serum usteki nal): | | & antibodies-to | -UST (ATU). |
| Date of Last Dose (mm/dd/yyyy) Dose | _ | • | | izumab (RZB) | & antibodies-to | Nev o-RZB (ATR) |
| mm/dd/yyyy Dose | | | ing - Biologic | Dosing Data | (optional) | |
| RiskImmune®† (#3600) Assesses genetic predisposition to immunogenicity to anti-TNF therapy. TPMT Genetics¹ (#3300) Aids in individualized thiopurine dosing based on patient TPMT genotype. TPMT Enzyme (#3320) Phenotyping test that aids in individualized thiopurine dosing. Thiopurine Metabolites (#3200) Aids in optimization of thiopurine dosing to achieve clinical response. Current Thiopurine Dosing (optional) G-MP | | | | | | |
| Assesses genetic predisposition to immunogenicity to anti-TNF therapy. TPMT Genetics* (#3300) Aids in individualized thiopurine dosing based on patient TPMT genotype. TPMT Enzyme (#3320) Phenotyping test that aids in individualized thiopurine dosing. Thiopurine Metabolites (#3200) Aids in optimization of thiopurine dosing to achieve clinical response. Current Thiopurine Dosing (optional) Gemp mg/day AZA mg/day Other mg/day - Celiac, Bile Acid Malabsorption, Liver & Lactase Non-Persistence Celiac PLUS* (#6360) Includes Celiac Genetics* (#6260) Genetic profile to aid diagnosis of celiac disease. ONLY Celiac Serology (#155) Antibody profile to aid diagnosis of celiac disease. ONLY the following designated component(s) of Celiac Serology — Anti-Human Tissue Transglutaminase IgA (tTG IgA) (#1405) Anti-Endomysial IgA (EMA IgA) (#1505) Total serum IgA (#1605) DGP IgA (#1255) DGP IgG (#1355) 7C4 Diagnostic (#8205) Measures 7a-hydroxy-4-cholesten-3-one (7C4) to determine if bile acimalabsorption may be the underlying cause of Gl symptoms. FIBRO Spect* HCV (#4000) Assessment of liver fibrosis severity for NASH patients. FIBRO Spect* (#6100) Genetic test that aids in identification of primary lactase non-persistence. Miscellaneous Testing Other Prometheus Testing*: 'Acknowledgment of informed consent required if genetic testing is indicated above | (IIIII) | , уууу) | 20 | □mg | inte | □days □week |
| Current Thiopurine Dosing (optional) □ 6-MP | ☐ TPM Phenoty | T Enzyme yping test that a | (#3320) aids in individual | ized thiopurin | e dosing. | |
| □ 6-MP | Alds III | | | | | . |
| Celiac PLUS[†] (#6360) Includes Celiac Genetics and Celiac Serology. □ ONLY Celiac Genetics[†] (#6260) Genetic profile to aid diagnosis of celiac disease. □ ONLY Celiac Serology (#1155) Antibody profile to aid diagnosis of celiac disease. □ ONLY the following designated component(s) of Celiac Serology — □ Anti-Human Tissue Transglutaminase IgA (tTG IgA) (#1405) □ Anti-Endomysial IgA (EMA IgA) (#1505) □ Total serum IgA (#1605) □ DGP IgA (#1255) □ DGP IgG (#1355) □ TC4 Diagnostic (#8205) ■ Measures 7α-hydroxy-4-cholesten-3-one (7C4) to determine if bile acimalabsorption may be the underlying cause of GI symptoms. □ FIBRO Spect® HCV (#4000) | П 6-MP | | | | | ma/da |
| Celiac PLUS[†] (#6360) Includes Celiac Genetics and Celiac Serology. □ ONLY Celiac Genetics[†] (#6260) Genetic profile to aid diagnosis of celiac disease. □ ONLY Celiac Serology (#1155) Antibody profile to aid diagnosis of celiac disease. | | mg/ddy | | 1119/ day_ | | 1119/44 |
| Measures 7α-hydroxy-4-cholesten-3-one (7C4) to determine if bile acimalabsorption may be the underlying cause of GI symptoms. FIBRO Spect® HCV (#4000) Assessment of liver fibrosis severity for HCV patients. FIBRO Spect® NASH (#4100) Assessment of liver fibrosis severity for NASH patients. Lacto TYPE®† (#6100) Genetic test that aids in identification of primary lactase non-persistence. Miscellaneous Testing Other Prometheus Testing†: †Acknowledgment of informed consent required if genetic testing is indicated above | Include ONL' Gene ONL' Antik OONL' Antik Anti-I | s Celiac Genet Y Celiac Gene etic profile to ai Y Celiac Serol body profile to NLY the followir Human Tissue Tr Endomysial IgA | ics and Celiac Stics† (#6260) d diagnosis of ogy (#1155) aid diagnosis on g designated consignated consignated consignated consignated consignated consignated consignated consignations. | celiac diseason f celiac diseason omponent(s) | se. of Celiac Serolo (#1405) | |
| Assessment of liver fibrosis severity for HCV patients. FIBRO Spect® NASH (#4100) | Measur | res 7 α -hydroxy | /-4-cholesten- | | | if bile acid |
| Assessment of liver fibrosis severity for NASH patients. Lacto TYPE®† (#6100) Genetic test that aids in identification of primary lactase non-persistence. Miscellaneous Testing Other Prometheus Testing†: †Acknowledgment of informed consent required if genetic testing is indicated above | | | | | ents. | |
| Genetic test that aids in identification of primary lactase non-persistence. Miscellaneous Testing Other Prometheus Testing†: †Acknowledgment of informed consent required if genetic testing is indicated abov | | | | | ients. | |
| Other Prometheus Testing†: †Acknowledgment of informed consent required if genetic testing is indicated abov | | | | of primary lac | tase non-persis | tence. |
| †Acknowledgment of informed consent required if genetic testing is indicated abov | | | Miscellaneo | us Testing | | |
| | *Ackno | wledgment of in | formed consent | required if gen | | |

Specimen collection requirements on page 2 —

[†]Acknowledgment of informed consent for genetic testing required. *Failure to provide the required data, at the time of sample collection, may result in reporting delay/cancellation.

| Specimen Collection and Handling Procedures | | | | | | | | |
|---|---------------------------------|---|---|---|---|--|--|--|
| Test Ordered | Turnaround Time ^a | Transport Kit and Storage Conditions | Specimen Type and Volume | Specimen Collection Tube | Specimen Stability | | | |
| 7C4 Diagnostic | 7 days | Cold pack REQUIRED Do not freeze | 1.0 mL Serum | Serum Separator Tube or Red-Top Tube | Room temp: 3 days Refrigerated: 7 days | | | |
| Anser ADA, IFX, RZB, UST, VDZ | 3 days | Ambient or cold pack <u>Do not freeze</u> | 2.0 mL Serum (0.5 mL for Peds) | Serum Separator Tube or Red-Top Tube | Room temp: 14 days Refrigerated: 14 days | | | |
| Celiac PLUS [†] | 4 days | Ambient or cold pack <u>Do not freeze</u> | 2.0 mL Serum AND 2.0 mL Whole Blood | Serum Separator Tube or Red-Top Tube AND EDTA/Lavender-Top Tube | Room temp: 7 days Refrigerated: 30 days | | | |
| Celiac Genetics [†] | 4 days | Ambient or cold pack <u>Do not freeze</u> | 2.0 mL Whole Blood | EDTA/Lavender-Top Tube | Room temp: 7 days Refrigerated: 30 days | | | |
| Celiac Serology (including all components) | 4 days | Ambient or cold pack <u>Do not freeze</u> | 2.0 mL Serum (0.5 mL for peds) | Serum Separator Tube or Red-Top Tube | Room temp: 7 days Refrigerated: 30 days | | | |
| Crohn's Prognostic† | 7 days | Ambient or cold pack <u>Do not freeze</u> | 2.0 mL Serum AND 2.0 mL Whole Blood | Serum Separator Tube or Red-Top Tube AND EDTA/Lavender-Top Tube | Room temp: 7 days Refrigerated: 7 days | | | |
| FIBRO <i>Spect</i> HCV, NASH | 7 days | Ambient or cold pack <u>Do not freeze</u> | 2.0 mL Serum (0.5 mL for peds) | Serum Separator Tube or Red-Top Tube | Room temp: 7 days Refrigerated: 30 days | | | |
| IBD sgi Diagnostic*† | 4 days | Ambient or cold pack <u>Do not freeze</u> | 2.0 mL Serum AND 2.0 mL Whole Blood | Serum Separator Tube or Red-Top Tube AND EDTA/Lavender-Top Tube | Room temp: 7 days Refrigerated: 21 days | | | |
| Lacto TYPE† | 7 days | Ambient or cold pack <u>Do not freeze</u> | 2.0 mL Whole Blood | EDTA/Lavender-Top Tube | Room temp: 7 days Refrigerated: 30 days | | | |
| Monitr® Crohn's Disease | 5-7 days | Cold pack preferred <u>Do not freeze</u> | 2.0 mL SPUN Serum | SPUN Serum Separator Tube | Room temp: 3 days Refrigerated: 14 days | | | |
| RiskImmune*† | 4 days | Ambient or cold pack. <u>Do not freeze</u> | 2.0 mL Whole Blood | EDTA/Lavender-Top Tube | Room temp: 10 days Refrigerated: 30 days | | | |
| Thiopurine Metabolites | 3 days | Cold pack preferred <u>Do not freeze</u> | 5.0 mL Whole Blood | EDTA/Lavender-Top Tube | Room temp: 24 hours Refrigerated: 8 days | | | |
| TPMT Enzyme | 3 days | Cold pack preferred <u>Do not freeze</u> | 5.0 mL Whole Blood | EDTA/Lavender-Top Tube | Room temp: 24 hours Refrigerated: 8 days | | | |
| TPMT Genetics† | 4 days | Ambient or cold pack <u>Do not freeze</u> | 2.0 mL Whole Blood | EDTA/Lavender-Top Tube | Room temp: 10 days Refrigerated: 30 days | | | |

^aBusiness days from date of receipt.

SHIPPING INSTRUCTIONS: Prometheus has an agreement with FedEx* for express overnight delivery within the United States and Canada. Please call FedEx at 1-800-GoFedEx (463-3339) to schedule a pickup. FedEx will pick up your specimens and ship them to Prometheus Laboratories Inc. in San Diego at no expense to you. Prometheus will provide specimen transportation kits upon request. NOTE: Multiple specimens may be shipped in a single transportation kit. For more information, call Client Services at 888-423-5227, or go to prometheuslabs.com.

ACKNOWLEDGMENT OF INFORMED CONSENT FOR GENETIC TESTING

I warrant that this test was ordered and that I have obtained the appropriate prior written consent. This written consent was signed by the person who is the subject of the test (or if that person lacks capacity to consent, signed by the person authorized to consent for that person) and includes the following (unless certain that the following information is not required by the state in which I practice):

- 1. The purpose of this test is to determine if the patient may have a variant in the gene(s) being tested, which has been found to be associated with this condition.
- 2. This test will only test for this specific condition and will not detect ALL possible variants within this gene, nor will it detect variants in other genes.
- 3. Prior to my signature of the written consent, a qualified healthcare professional discussed with the patient the genetic test ordered and described the steps involved in the test, the constraints of the procedure, and its accuracy.
- 4. My patient was advised by a qualified healthcare professional of the risks and benefits of genetic testing, and advised of the significance of a positive and negative result.
- 5. The patient understands that a positive test result is an indication that the patient may be predisposed to, or have, the condition listed.
- 6. The patient understands that the test may fail, that the results may be non-informative or not predictive for his/her case, and that the test may reveal information that is unrelated to their intended purpose.
- 7. No unauthorized test is performed on specimens.
- 8. NY-state specimens will be destroyed within 60 days after collection when no longer required for clinical purposes.
- 9. The informed consent does not authorize the use or release of any other identified medical information unrelated to this genetic test
- 10. The patient understood that he/she could see professional genetic counseling prior to undergoing the testing procedure, and received written information identifying a genetic counselor or medical geneticist by his/her treating provider.

[†]Acknowledgment of informed consent for genetic testing required.

Specimens should be labeled with 2 identifiers and date of collection. Examples of acceptable identifiers include, but are not limited to: patient name, date of birth, hospital number, requisition, accession, or unique random number. Unlabeled specimens will not be accepted for testing.

SHIPPING INSTRUCTIONS: Prometheus has an agreement with FedEx* for express overnight delivery within the United States and Canada. Please call FedEx at 1-800-GoFedEx (463-3339)